Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

EBMT 2020 | CASSIOPEIA: D-VTD in high-risk multiple myeloma

Aurore Perrot • 31 Aug 2020
EBMT 2020
Multiple Myeloma Antibodies Bortezomib Daratumumab Dexamethasone Thalidomide
CASSIOPEIA

Aurore Perrot, MD, PhD, University Hospital Antwerp, Vandoeuvre-lès-Nancy, France, discusses the CASSIOPEIA study (NCT02541383) evaluating the use of daratumumab plus bortezomib, thalidomide, and dexamethasone (D-VTD) in autologous transplant-eligible newly-diagnosed multiple myeloma. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Aurore Perrot

The role of transplant in myeloma 0:48
The role of transplant in myeloma
Aurore Perrot • 9 Sep 2021
Real-world data: treatment pathways for myeloma patients in France 2:23
Real-world data: treatment pathways for myeloma patients in France
Aurore Perrot • 9 Sep 2021
Moving towards a cure for myeloma 0:40
Moving towards a cure for myeloma
Aurore Perrot • 9 Sep 2021
IFM 209 update: 4-year extended follow-up of transplantation outcomes in myeloma 5:24
IFM 209 update: 4-year extended follow-up of transplantation outcomes in myeloma
Aurore Perrot • 7 Dec 2020

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals